Assistant Editor, OncLive®
Jessica joined the company in August 2019 and is one of the point contacts for the OncLive On Air™ podcast. She is a Rider University alumna and holds a degree in journalism and biology. Prior to joining MJH Life Sciences, she interned with the Ireland-based social media monitoring agency Olytico and served as a copy editor and writer for The Rider News. Email: jhergert@onclive.com
Nuanced Decision-Making Strategies Are Needed as the Multiple Myeloma Paradigm Grows
February 11th 2022Saad Z. Usmani, MD, MBA, FACP, shares key takeaways from presentations given during the meeting on the evolving paradigms of frontline, early relapsed, and late relapsed multiple myeloma, the current role of bispecific antibodies and CAR T-cell therapy, and emerging immunotherapies and also trials in progress in the space.
Read More
Expanded Combinations, Novel Agents, and MRD-Informed Trials Transform Myeloma Paradigm
February 11th 2022Laura Finn, MD, provides a deep dive into pivotal data with combinations and novel agents that have changed the paradigm for patients with newly diagnosed, early relapsed, and late relapsed multiple myeloma.
Read More
Advances Improve Outcomes but Leave Space for Curative Strategies in Metastatic Breast Cancer
February 11th 2022John T. Cole, MD, discusses how updates in HER2-positive breast cancer have affected sequencing strategies, selecting between CDK4/6 inhibitors in the adjuvant and metastatic settings of hormone receptor HR–positive breast cancer, and the need for additional therapies in triple-negative breast cancer.
Read More
Personalized Medicine Approaches Continue to Gain Steam in BRAF/NRAS+ Metastatic Melanoma
February 9th 2022Meredith McKean, MD, MPH, discusses how the presence of atypical BRAF mutations affects treatment selection in patients with metastatic melanoma, highlighted the ongoing KN-8701 trial, and explained why developments in this space further solidify the importance of broad molecular profiling.
Read More
Brachytherapy Represents a Potential Strategy in AYA Patients With Rhabdomyosarcoma
February 9th 2022Although brachytherapy is rarely utilized as a treatment for pediatric and adolescent/young adult patients in the United States, AYA patients with rhabdomyosarcoma treated with BT had favorable survival outcomes.
Read More
Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC
February 7th 2022Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.
Read More
Debra L. Richardson, MD, FACS, FACOG, discusses the role of NaPi2b as a target for upifitamab rilsodotin, data that have emerged from the ongoing phase 1/2 UPLIFT trial, and the development of other studies like UPNEXT and UPGRADE that are further evaluating upifitamab rilsodotin in patients with ovarian cancer.
Read More
RNA-Based NGS Offers the Potential to Identify More Patients With Rare Alterations in NSCLC
February 4th 2022The field of non–small cell lung cancer has exploded with continuous advances in targeted therapies directed toward key molecular alterations, including rare mutations like MET exon 14 skipping mutations, RET rearrangements, and ROS1 mutations.
Read More
Laura Spring, MD, discusses the influence of the findings from the DESTINY-Breast03 trial with trastuzumab deruxtecan on practice patterns in HER2-positive breast cancer, updates in the management of brain metastases, and ongoing clinical trials she is keeping an eye on to move therapies into earlier lines of treatment.
Read More
Sequencing Strategies Shift in Metastatic HER2+ Breast Cancer
February 1st 2022Ruta D. Rao, MD, discusses factors that inform treatment selection for patients with metastatic HER2-positive breast cancer, the effects key data that emerged in 2021 have had on sequencing, strategies to mitigate toxicities associated with trastuzumab deruxtecan, and remaining questions regarding sequencing that may be the focus of ongoing research effort.
Read More
Immunotherapy Approvals Signal a Need for Molecular Testing in Endometrial Cancer
January 31st 2022Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.
Read More
Trastuzumab Deruxtecan Stands Out for HER2+ and HER2-Low Breast Cancer
January 25th 2022Aditya Bardia, MD, MPH, discusses the clinical implications of the DESTINY-Breast03 trial, the encouraging data from the DAISY trial, and sequencing questions that remain in the evolving paradigm of HER2-positive breast cancer.
Read More
Nivolumab/Ipilimumab Showcases Prolonged Treatment-Free Survival in Advanced RCC
January 24th 2022Over a 42-month period, the combination of nivolumab and ipilimumab induced a longer treatment-free survival compared with sunitinib (Sutent) when used as frontline therapy in patients with advanced renal cell carcinoma.
Read More
Durvalumab Plus Chemotherapy Improves Survival in Advanced Biliary Tract Cancer
January 18th 2022Treatment with the PD-L1 inhibitor durvalumab in combination with gemcitabine and cisplatin resulted in significantly improved overall survival vs placebo plus chemotherapy in patients with advanced biliary tract cancer.
Read More
Brufsky Underscores Practicing-Changing Data in HER2+ Metastatic Breast Cancer
January 17th 2022Adam M. Brufsky, MD, PhD, FACP, discusses the significance of the data from DESTINY-Breast03 with trastuzumab deruxtecan vs T-DM1 for patients with metastatic HER2-positive breast cancer, as well as how the findings set the field up to improve outcomes for patients with brain metastases.
Read More
Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis
January 13th 2022Tomer Mark, MD, discusses the emerging role of minimal residual disease as a surrogate end point in multiple myeloma, treatment selection for patients with newly diagnosed, early relapsed, and late relapsed disease, and the importance of daratumumab being introduced to the treatment paradigm of amyloidosis.
Read More
Incorporation of Chemotherapy-Free Regimens Improve Outcomes in Hematologic Malignancies
January 13th 2022Thomas Kipps, MD, PhD, discussed navigating treatment regimens in CLL and MCL, the success of brentuximab vedotin in Hodgkin lymphoma, choosing between TKIs in CML, and the importance of transfusion independence in MDS.
Read More
NSCLC Paradigm Progresses With Adjuvant Treatment and Overcoming Resistance
January 10th 2022As the armamentarium of advanced non–small cell lung cancer () continues to grow with the addition of novel targeted therapies for rare patient subtypes, the field is simultaneously shifting to evaluate targeted therapy and immunotherapy in earlier lines of treatment, including the neoadjuvant and adjuvant spaces.
Read More
Melissa Geller, MD, MS, and colleagues discuss key clinical trials that have changed the landscapes of HER2-positive breast cancer and triple-negative breast cancer, the role of first- and second-line maintenance therapy in ovarian cancer, and key updates in cervical and endometrial cancers.
Read More
Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI Cancers
January 6th 2022Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.
Read More
Bispecific Antibodies Hold Promise in HER2+ Breast Cancer
January 5th 2022Sara M. Tolaney, MD, MPH, discusses the mechanism of action that makes bispecific antibodies an intriguing approach in managing HER2-positive breast cancer, efficacy data with zanidatamab that were presented during the 2021 SABCS, and her thoughts on sequencing strategies with bispecific antibodies among other agents in the paradigm.
Read More
Adam M. Brufsky, MD, PhD, FACP, discusses the rationale to evaluate enobosarm in estrogen receptor–positive, androgen receptor–positive metastatic breast cancer, prior data observed with the agent, and the unmet needs positive results of the ARTEST trial could potentially fulfill.
Read More